Bharat, TJU partnering on COVID-19 vaccine

By The Science Advisory Board staff writers

May 20, 2020 -- Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.

The vector used in the new COVID-19 vaccine is an existing deactivated rabies vaccine, which was invented at the university. It's being used because it produces a strong immune response and is approved for use in children and adults, including pregnant women.

The vaccine showed a strong antibody response in mice, and researchers are testing whether vaccinated animals are protected from SARS-CoV-2 infection. Results are expected in June. Bharat Biotech aims to get into human trials as soon as December 2020.

Bharat Biotech has exclusive rights to develop, market, and deliver TJU's vaccine across the world, excluding the U.S., Europe, and Japan. The university continues to look for partners in those countries.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?